Stocks and Investing Stocks and Investing
Thu, January 25, 2024

Colin Bristow Downgraded (BIIB) to Hold and Decreased Target to $276 on, Jan 25th, 2024


Published on 2024-10-28 08:33:15 - WOPRAI, Colin Bristow
  Print publication without navigation


Colin Bristow of UBS, Downgraded "Biogen Inc." (BIIB) to Hold and Decreased Target from $311 to $276 on, Jan 25th, 2024.

Colin has made no other calls on BIIB in the last 4 months.



There are 10 other peers that have a rating on BIIB. Out of the 10 peers that are also analyzing BIIB, 1 agrees with Colin's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $239 on, Thursday, November 9th, 2023


These are the ratings of the 9 analyists that currently disagree with Colin


  • Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $311 on, Wednesday, December 20th, 2023
  • Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $295 on, Monday, December 18th, 2023
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $287 on, Thursday, December 14th, 2023
  • Danielle Brill of "Raymond James" Upgraded from Hold to Buy and Held Target at $283 on, Thursday, December 7th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $373 on, Friday, November 10th, 2023
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $365 on, Thursday, November 9th, 2023
  • Evan Seigerman of "BMO Capital" Maintained at Buy with Decreased Target to $295 on, Thursday, November 9th, 2023
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $363 on, Thursday, November 9th, 2023
  • Ami Fadia of "Needham" Reiterated at Strong Buy and Held Target at $305 on, Thursday, October 26th, 2023
Contributing Sources